[{"address1": "10170 Church Ranch Way", "address2": "Suite 100", "city": "Westminster", "state": "CO", "zip": "80021", "country": "United States", "phone": "720 940 2200", "website": "https://www.arcabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.", "fullTimeEmployees": 3, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas A. Keuer", "age": 64, "title": "President, COO & Principal Executive Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 400802, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. C. Jeffrey Dekker CPA", "age": 58, "title": "CFO, Treasurer & Company Secretary", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 323072, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://phx.corporate-ir.net/phoenix.zhtml?c=109749&p=irol-irhome", "maxAge": 86400, "priceHint": 4, "previousClose": 3.92, "open": 4.0, "dayLow": 3.9, "dayHigh": 4.36, "regularMarketPreviousClose": 3.92, "regularMarketOpen": 4.0, "regularMarketDayLow": 3.9, "regularMarketDayHigh": 4.36, "exDividendDate": 1724630400, "beta": 0.895, "forwardPE": -0.47272724, "volume": 445245, "regularMarketVolume": 445245, "averageVolume": 101377, "averageVolume10days": 203000, "averageDailyVolume10Day": 203000, "bid": 4.13, "ask": 4.27, "bidSize": 100, "askSize": 100, "marketCap": 60349532, "fiftyTwoWeekLow": 1.56, "fiftyTwoWeekHigh": 4.49, "fiftyDayAverage": 3.2972, "twoHundredDayAverage": 2.5205, "currency": "USD", "enterpriseValue": 27090714, "floatShares": 4788228, "sharesOutstanding": 14507100, "sharesShort": 4395829, "sharesShortPriorMonth": 4175393, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.303, "heldPercentInsiders": 0.0128999995, "heldPercentInstitutions": 1.01464, "shortRatio": 38.9, "shortPercentOfFloat": 0.4239, "impliedSharesOutstanding": 14507100, "bookValue": 2.245, "priceToBook": 1.8530067, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -7200000, "trailingEps": -0.49, "forwardEps": -8.8, "lastSplitFactor": "1:18", "lastSplitDate": 1554336000, "enterpriseToEbitda": -3.154, "52WeekChange": 1.0492611, "SandP52WeekChange": 0.2709713, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ABIO", "underlyingSymbol": "ABIO", "shortName": "ARCA biopharma, Inc.", "longName": "ARCA biopharma, Inc.", "firstTradeDateEpochUtc": 871047000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "aefe4f03-299b-3999-a469-92fced461200", "messageBoardId": "finmb_26198824", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.16, "recommendationKey": "none", "totalCash": 33283000, "totalCashPerShare": 2.294, "ebitda": -8589000, "totalDebt": 24000, "quickRatio": 26.186, "currentRatio": 26.609, "debtToEquity": 0.074, "returnOnAssets": -0.14351, "returnOnEquity": -0.20053, "freeCashflow": -4978250, "operatingCashflow": -6887000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-26"}]